Pharmacogenomics in cancer therapy: is host genome variability important?

Pharmacogenomics aims to elucidate the genomic determinants of drug disposition and effect. Because cancer chemotherapy is relatively nonspecific and has narrow therapeutic indices, there is great potential for pharmacogenomics to improve treatment outcomes by either reducing toxicity or increasing...

Full description

Saved in:
Bibliographic Details
Published in:Trends in pharmacological sciences (Regular ed.) 2004-09, Vol.25 (9), p.457-464
Main Authors: Petros, William P., Evans, William E.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Genetic Variation
Humans
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Pharmacogenetics
Polymorphism, Genetic
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pharmacogenomics aims to elucidate the genomic determinants of drug disposition and effect. Because cancer chemotherapy is relatively nonspecific and has narrow therapeutic indices, there is great potential for pharmacogenomics to improve treatment outcomes by either reducing toxicity or increasing efficacy. The diversity of therapeutic targets for anticancer drugs and the intensity of clinical pharmacology research in oncology have provided many examples of clinically relevant pharmacogenomic applications. Important elements that are discussed in this article include the association of genetic variability in the metabolism, intracellular transport and targets of anticancer drugs. In addition, we summarize where the field stands currently, and how information from the host and tumor might be integrated into decision making.
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2004.07.007